Blog
RSS FeedPosted by Michael Wonder on 14 Jul 2021
NICE feedback?
13 July 2021 - NICE is quite far along a NICE led process to review its methods and processes for ...
Posted by Michael Wonder on 16 Jan 2021
Strengthening patient outcome evidence in health technology assessment: a coproduction approach
13 January 2021 - NICE worked with patients and staff from six patient organisations to review existing health technology assessment ...
Posted by Michael Wonder on 25 Jun 2020
‘Open dialogue’ needed with HTAs to improve access
25 June 2020 - Having worked in the NHS as a hospital pharmacist before moving into market access roles in ...
Posted by Michael Wonder on 31 Jul 2019
Patient preferences studies: how NICE aims to make use of them
2 July 2019 - Dr Jacoline Bouvy, Senior Scientific Adviser, talks about a growing area of interest for the Scientific ...
Posted by Michael Wonder on 27 Jul 2019
Stories of patient involvement impact in health technology assessments: a discussion paper
24 July 2019 - As more health technology assessment bodies seek to implement patient involvement, there is a desire to learn ...
Posted by Michael Wonder on 01 Jul 2019
Ethical challenges related to patient involvement in health technology assessment
28 June 2019 - Including information and values from patients in HTA has the potential to improve both the process and ...
Posted by Michael Wonder on 14 Feb 2019
NICE provides first scientific advice on patient preference study design
14 February 2019 - The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided ...
Posted by Michael Wonder on 18 Jan 2019
Patient groups fail to declare financial interests during NICE assessments
16 January 2019 - Patients’ groups involved in assessing treatments for the NHS often fail to disclose their financial interests, ...
Posted by Michael Wonder on 26 Oct 2017
Exploration and preferential ranking of patient benefits of medical devices: a new and generic instrument for health economic assessments
25 October 2017 - For medical devices, benefits other than direct clinical effects may have a large impact on the patients’ ...
Posted by Michael Wonder on 26 Oct 2017
Taking patient heterogeneity and preferences into account in health technology assessments
25 October 2017 - The INTEGRATE-HTA project provided methodology to evaluate complex technologies. ...
Posted by Michael Wonder on 26 Sep 2017
Drugs watchdog NICE attacks pharmaceutical industry in pricing dispute
25 September 2017 - Industry expert’s evidence is not independent, NICE argues. ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for azacitidine (Vidaza) for patients with acute myeloid leukaemia
8 April 2016 - The Department of Health has asked NICE to produce guidance on the use of azacitidine in the ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for mepolizumab (Nucala) for patients with severe eosinophilic asthma
4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in ...
Posted by Michael Wonder on 04 Jan 2016
NICE public board meeting and NICE question time – Salisbury
4 January 2016 - Every two months the NICE Board holds its meeting in a different venue; moving from region to ...
Posted by Michael Wonder on 25 Nov 2015
NICE consults on ovarian cancer treatments draft guidance
24 November 2015 - The draft guidance gives provisional recommendations on whether paclitaxel, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, trabectedin and ...